Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 15/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | ITK | Q08881 | 1/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1849237 | 1.00 | SYK (0.62) | SYKEGFRITKPDE4BPDE4A | |
| SCHEMBL1853038 | 0.92 | SYK (0.61) | SYKEGFRITKPDE4BPDE4A | |
| SCHEMBL1853033 | 0.91 | SYK (0.61) | SYKEGFRITKPDE4BPDE4A | |
| SCHEMBL1352375 | 0.91 | SYK (0.61) | SYKEGFRITKPDE4BPDE4A | |
| SCHEMBL1845989 | 0.90 | SYK (0.59) | SYKEGFRITK | |
| SCHEMBL1845992 | 0.90 | SYK (0.59) | SYKEGFRITK | |
| SCHEMBL1847523 | 0.84 | SYK (0.60) | SYKEGFRITK | |
| SCHEMBL1847521 | 0.84 | SYK (0.62) | SYKEGFRITK | |
| SCHEMBL1355070 | 0.84 | SYK (0.62) | SYKEGFRITK | |
| SCHEMBL1849391 | 0.83 | SYK (0.57) | SYKEGFRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323993-A2 | 2,6-DIAMINO- PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | Portola Pharmaceuticals, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2009136995-A2 | INHIBITORS OF SYK PROTEIN KINASE | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |